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Introduction 
 
Critical illness, constituting an acute illness or injury resulting in organ dysfunction 
and failure, is associated with a profound, systemic activation of the immune system 
and inflammation-mediated organ damage [1].  However, critically ill patients also 
suffer a high rate of nosocomial infection with secondary sepsis being a common 
cause of death [2].   This high prevalence of secondary infections argues for the 
influence of an immune suppression that may, at first glance, appear paradoxical in 
light of the pro-inflammatory nature of many critical illnesses.  Although immune cell 
hypo-function has been noted in clinical and experimental critical illnesses, the 
mediators of these effects remain poorly defined.   This review will present the recent 
evidence accumulating for the role of pro-inflammatory mediators in driving immune 
dysfunction, and how this insight may, in part, explain the apparent paradox of 
immune suppression occurring in a patient with manifestations of hyperinflammation 
[3]. 
 
Nosocomial infection in intensive care 
Estimates of the prevalence of nosocomial infection amongst general medical and 
surgical patients range from 4-6% [4] In striking contrast, amongst patients requiring 
organ support in intensive care units (ICU), the prevalence rises to 25-40% [2,5].  
These latter rates are similar to those found in frank neutropaenia [6]. Although 
attributing direct mortality to nosocomial infection remains problematic one infection 
alone, Ventilator Associated Pneumonia (VAP), has an estimated mortality of 20-30% 
[7].  This high prevalence of nosocomial infection, combined with the frequency of 
otherwise commensal organisms amongst the infecting organisms [5] suggests a 
profound degree of immune suppression. 
 
Systemic inflammation and immune suppression in critical illness 
Critical illness is frequently associated with a systemic inflammatory response 
syndrome (SIRS), characterised by physiological manifestations of inflammation 
(altered temperature, leukocytosis or bone marrow suppression, tachycardia and 
tachypnoea).  This is accompanied by biochemical and immunological evidence of 
immune system activation [1,8,9], and can be precipitated by both sterile and infective 
insults.  Despite disparate initiating events, the stereotyped SIRS response arises from 
final common pathways, with the release of endogenous inflammatory mediators 
including tumour necrosis factor (TNF-a) interleukins 1,6, and 8 and complement 
activation [1,8,9,10].   
 
Prompted by the failures of therapies aimed at neutralizing these pro-inflammatory 
mediators, the concept of a counter-regulatory but equally maladaptive anti-
inflammatory response  known as ‘compensatory anti-inflammatory response 
syndrome’ (CARS) was proposed [11].  The general conception has been of SIRS-
CARS being a biphasic process with inflammation being followed by immune 
hypoactivity and recovery occurring as the immune hypofunction resolved [12]. 
However, whilst the biphasic SIRS-CARS continuum provided an interesting 
theoretical framework, it lacks experimental demonstration and does not fit with the 
clinical picture seen amongst critically ill patients in the intensive care unit.    
Clinically many patients show signs of persisting inflammation, and immune 
mediated organ damage whilst simultaneously remaining highly susceptible to 
secondary infections, suggesting the term Complex Immune Dysfunction Syndrome 
(CIDS). 
 
Immune hypoactivity has now been demonstrated in virtually all immune cell types, 
including innate actors such as neutrophils [13,14], monocytes [15], tissue 
macrophages [16] and dendritic cells [17] as well as in the adaptive immune system in 
T cells [18], B cells [19] and NK cells [20], a summary of the defects found is shown 
in table 1.   However it is undoubtedly true that critical illness is associated with a 
profound degree of immune activation and systemic inflammation [1]. 
 
One possible reason for the variable and apparently contradictory findings of immune 
cell function from different reports may be the time point at which the measurement is 
made.  In animal models, where pre-morbid sampling is feasible and there is certainty 
over time and severity of onset, most studies indicate a rapid pro-inflammatory 
response with immune cell activation/hyperactivity with later onset of hypoactivity 
[12].  In human studies, monocyte deactivation is largely reported to occur several 
days after admission to intensive care [21], as are T cell impairments [22].  However 
this is not universally the case and apparently ‘early onset’ immune suppression is 
noted in some reports [23,24].  In these latter cases it is possible that the early 
‘hyperactive’ phase may well have been missed in the pre-ICU period. What is also 
clear is that the ‘immune status’ (i.e. hyper- or hypo-active) may depend on which 
aspect of cellular function is examined, with increasing evidence that both pro- and 
anti-inflammatory mediators may be elevated at the same time [25]. 
 
 
Neutrophils –exemplars of the hyper/hypoinflammatory duality 
Of the immune cells discussed above, one type in particular appears to exemplify this 
apparent dualistic state by demonstrating features of both activation and dysfunction 
simultaneously – the neutrophil. Organ dysfunction in critically ill patients is, to a 
considerable degree, driven by neutrophils (Brown et al 2006). These key immune 
cells tend to display surface markers of ‘activation’, notably elevated levels of CD11b 
and CD64 and diminished CD16 in critical illness [26], although one study has also 
demonstrated diminished inducibility of these receptors [27]. Neutrophils from 
critically ill patients demonstrate enhanced release of proteolytic enzymes such as 
human neutrophil elastase (HNE) in response to ex-vivo LPS [28] with elevated levels 
also being seen in patient plasma [29].  Similar findings are made when examining 
other neutrophil granule contents such as myeloperoxidase [30]. Despite their 
accumulation and damage of organs, neutrophils from critically ill patients display 
impaired transmigration and chemotaxis [31].  
 
In recent work by our group we have demonstrated that, in patients with the severe 
nosocomial infection VAP, their neutrophils exhibit a profound impairment of 
phagocytic ability and ROS production [13].  However the same neutrophils also 
expressed enhanced surface markers of ‘activation’ (elevated CD11b, CD64, 
decreased CD16), induced greater inflammation in alveolar cells [13] whilst the 
patients had higher levels of plasma HNE and myeloperoxidase.  This dualistic 
dysfunction was not restricted to the plasma compartment, as alveolar neutrophils 
demonstrated a similar impairment in phagocytosis [13], whilst alveolar fluid had 
high levels of alveolar inflammatory cytokines [32] and the neutrophil derived 
enzymes HNE and MMP 8 and 9 [33].   This apparently paradoxical super-position of 
both pro-inflammatory activation and failure of key anti-microbial functions within 
the same cell type was illuminated by the finding that dysfunction was driven by an 
excess of the pro-inflammatory complement split product C5a [13]. 
 
C5a is a key mediator of neutrophil dysfunction 
C5a is an anaphylotoxin derived from complement C5, and is released in large 
quantities in a variety of diseases that can precipitate critical illness including sepsis, 
major trauma, pancreatitis and major surgery. C5a has a range of deleterious effects 
when released in large quantities, including activating the coagulation system via 
tissue factor and stimulating the production of inflammatory cytokines such as 
HMGB-1 [34]. C5a is also directly chemo-attractive to neutrophils as well as 
stimulating the release of reactive oxygen species (ROS) and lytic enzymes such as 
human neutrophil elastase (HNE) [35].  Both have been implicated in sepsis-
associated organ damage and outcomes [36].  C5a was demonstrated to be a key 
mediator of neutrophil dysfunction in animal models of sepsis [37], and more recently 
in humans with critical illness [13,14].   
 
C5a has a very short plasma half-life (2-3 mins), and is predominantly removed by 
binding to its major receptor CD88 which is then internalised by CD88-bearing cells 
[38].   This can make determining C5a levels and cellular exposure difficult.  
However the key finding that CD88 down-regulation relates to complement exposure 
and correlates with neutrophil function [13,14] allows determination of C5a mediated 
dysfunction in humans.  
 
Having identified C5a as a key mediator of neutrophil dysfunction, the question arises 
of clinical relevance and time course.  In the study of patients with suspected VAP 
[13] the samples were taken at the time of clinical suspicion, typically 8 days after 
admission to ICU, and therefore it was not possible to determine whether C5a-
mediated dysfunction preceded, or was a consequence of, nosocomial infection.  In 
addition, although immune depression is suggested to be a late phenomenon in critical 
illness [12], C5a release occurs early [39]. If the hypothesis is correct dysfunction 
should occur similarly early. 
 
The correlation between CD88 and impaired phagocytosis, the hallmark of C5a-
mediated neutrophil dysfunction in humans, was also found in samples taken earlier 
in the course of ICU admission [14], importantly before any ICU-acquired infection 
had occurred. Indeed neutrophil CD88 was below levels seen in healthy volunteers in 
the majority of patients at study admission (i.e. <48 hours after ICU admission), with 
counts tending to fall further during admission suggesting ongoing complement 
activation.  This was backed up by the finding of rising C3a (a proxy measure of C5a 
release) amongst patients with neutrophil dysfunction, in contrast to static or falling 
levels amongst those without dysfunction. These findings are suggestive of ongoing 
complement activation in the patients with neutrophil dysfunction/low CD88.  
 
Patients with C5a mediated neutrophil dysfunction had a considerably higher risk of 
nosocomial infection (RR 5.4 95% CI 1.4-21.0). Time-series analysis showed a 
significant difference between the two groups, with the dysfunction group showing a 
steady increase in infections over their stay whilst those without dysfunction remained 
relatively resistant to infection even if they remained in the ICU for some time [14].   
 A mechanism by which C5a impairs phagocytosis by neutrophils has recently been 
elucidated [13, 14]. Following ligation of CD88 the intra-cellular signalling system 
PI3K is activated.  The delta isoform then proceeds to impair the activation of the 
small GTPase RhoA that in turn inhibits the actin polymerisation required for 
phagocytosis. These defects have been demonstrated in both ex-vivo C5a treated 
neutrophils and those extracted from critically ill patients.  Intriguingly elevated intra-
cellular levels of cAMP, which can arise from excessive beta-agonist stimulation, also 
impair phagocytosis via the same mechanism [40] although the actions of C5a are 
independent of cAMP [13].  Importantly, the growth factor/cytokine GM-CSF is able 
to restore RhoA activity and thus rescue phagocytic ability in neutrophils [13,14].  
This provides a new potential therapeutic angle and is currently being tested in a 
clinical trial (Clinical Trial NCT01653665).   
 
Additional pro-inflammatory drivers of dysfunction 
In addition to C5a, other classically ‘pro-inflammatory’ molecules have been shown 
to drive neutrophil dysfunction. Formylated peptides, such as fMLP, are found in 
bacterial cell walls as well as those of mitochondria.   The fMLP receptor acts via the 
same G-coupled protein isoforms as the C5a receptor, namely the Gαi2 subunit and 
in-vitro can induce a similar defect in phagocytosis [13].   The recent finding of 
formylated peptides derived from the release of mitochondria following major trauma 
[41] suggests another way in which a precipitant of critical illness can induce both 
immune activation and hypoactivity simultaneously. 
 
 In patients with alcoholic hepatitis, another well-established cause of systemic 
immune activation that bears some comparison to sepsis, Mookerjee and colleagues 
demonstrated defects in neutrophil phagocytosis and reactive oxygen species (ROS) 
production [42].  These defects predicted the subsequent occurrence of nosocomial 
infections, and could be reproduced in healthy volunteer neutrophils by the 
application of patient plasma or directly with lipopolysaccharide  (LPS), and blocked 
by extracting LPS or inhibiting the LPS receptor CD14.    LPS hyporesponsiveness in 
monocytes, termed monocyte deactivation, is a well-characterised component of 
immune suppression in sepsis [15].  As LPS can itself induce a state of deactivation in 
monocytes, this could induce additional immuno-suppressive effects.  LPS is 
commonly found in plasma and other body fluids from critically ill patients, even in 
the absence of gram-negative infection. Indeed extra-corporeal LPS absorption with 
polymixin hemoperfusion has shown early promise in human sepsis [43].  
 
Additional mediators of immune dysfunction are likely to be identified over the next 
few years.  The alveolar space of patients with VAP demonstrates high levels of pro-
inflammatory molecules [32,33] and BALF from these patients can induce a defect in 
phagocytic and bactericidal functions of healthy donor neutrophils [13].   The nature 
of this pulmonary inhibitor is currently undetermined, although it acts in a C5a 
independent fashion [13]. 
 
The co-existence of immune dysfunction and inflammatory disease is not restricted to 
sepsis and similar precipitants of critical illness.  In HIV infection activation of 
complement has been associated with increased C5a, reduced neutrophil CD88 and 
impaired neutrophil function [44].   In other diseases with a major inflammatory 
components, including Crohn’s disease, chronic renal impairment and congestive 
cardiac failure, immune dysfunction is common [45,46]. 
  
Sepsis and SIRS result not only in immune activation but also activation of a number 
of other neuro-humeral systems, with the catecholamines being key mediators of the 
frequently seen tachycardia and hyperdynamic circulation.  Exogenous 
catecholamines and adrenergic drugs are regularly administered to patients to reverse 
vasodilatation, and later stage reductions in cardiac output.   Acting via beta-
receptors, these hormones and drugs can impair functions of neutrophils [13] and T 
cells [46].   Although these effects have not been definitively demonstrated in human 
sepsis, it is highly likely that part of the immune suppression seen is beta-adrenergic 
mediated.  This may explain the reductions in nosocomial infections seen in burns 
patients treated with propanolol [47] and some of the benefit of beta-blockers in 
animal models of sepsis  [48]. 
 
The influence of multiple immune dysfunctions 
Whilst there is growing evidence of the role of pro-inflammatory molecules directly 
mediating immune dysfunction, it is undoubtedly the case that a significant amount of 
immune failure arises from inappropriate or overly exuberant counter-regulatory anti-
inflammatory responses to the primary immune activation.   Elevated levels of 
regulatory T-cells, which inhibit T-cell proliferation, are found in sepsis and major 
trauma [22] and associated with poor outcomes.  Recent work has identified elevated 
levels of myeloid derived suppressor cells, dendritic cells and B-cells [49] although 
the influence of these specific findings on patient outcomes remains to be fully 
determined.   
 Immune cell dysfunctions do not occur in isolation.  Our group has recently 
demonstrated concurrent dysfunctions of monocytes, neutrophils and T-cells in a 
cohort of critically ill patients.  Whilst 11% of patients demonstrated no immune 
dysfunction, 23% had dysfunction of 1 cell type, 45% dysfunction of two cell types 
and 21% had dysfunction across all three cell types examined.  This cumulative 
burden of immune dysfunction was associated with a progressive increase in the risk 
of developing nosocomial infection, ranging from 0% amongst patients with no 
dysfunctions to 75% of those with all three [50].   It is likely that the effects of 
immune cell dysfunction are not simply additive, but synergistic.  
 
The field of immune failure in critical illness is relatively new, with much still to be 
determined.  Key questions that remain include the time course of dysfunction, 
especially the recovery phase and whether recovery is a pre-requisite for over-all 
recovery from critical illness and successful discharge from hospital.   Further work is 
required to clarify the relative contributions of different mediators of immune cell 
dysfunction, with this knowledge hopefully illuminating new therapeutic avenues.  It 
can be hoped that better characterisation of markers of immune failure will allow 
effective trials of targeted immuno-stimulatory and immuno-modulatory therapies, 
and this must remain a key focus for this field. 
 
The picture emerging from recent work on immune failure in critical illness is coming 
closer to describing the picture seen clinically, of systemic inflammation and 
inflammation mediated organ failure coupled with significant vulnerability to 
nosocomial infection and death from sepsis.  In a manner which can be considered 
analogous to disseminated intra-vascular coagulation, demonstrating both thrombosis 
and coagulopathy, we see a complex state of both pro and anti-inflammatory actions 
simultaneously and sometimes even in the same cell type.   
 
Conclusions 
Immune failure is key to understanding the pathophysiology of critical illness, and 
can be considered another organ failure.  Some of this is failure is driven by 
molecules which also drive the inflammatory response (e.g. C5a, LPS, fMLP). This 
may explain the duality of inflammation and immune suppression, immune mediated 
organ failures and susceptibility to nosocomial infection/death from sepsis. The 
classical conceptions of SIRS and CARS fail to adequately describe the situation at an 
immune cellular level.  We suggest that these concepts should be refined to reflect the 
reality of an immune failure where collateral host damage occurs simultaneously with 
markedly impaired anti-microbial defences.   The mixture of novel ‘pro-
inflammatory’ molecules driving cellular failure, alongside over-zealous counter-
regulatory processes is perhaps best described as a Complex Immune Dysfunction 
Syndrome (CIDS). 
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 Cell type Finding References 
Neutrophils Impaired phagocytosis, 
reactive oxygen species 
production, transmigration 
13, 24, 31, 35, 37 
Monocytes Reduced production of  
Tumour necrosis factor in 
response to LPS 
15, 21,23, 24  
Macrophages Reduced production of  
Tumour necrosis factor in 
response to LPS 
16 
T lymphocytes Decreased proliferative 
response, increased 
apoptosis, increased 
proportion of regulatory T 
cells 
12,18, 19, 22, 49 
B lymphocytes Impaired antigen-specific 
responses 
19 
Natural Killer cells Reduced cytokine 
responses to LPS 
20 
Dendritic cells Decreased antigen 
presentation 
19,49 
 
Table one: immune defects and immunosuppressive responses identified in 
patients and animal models of critical illness. 
 
 
